Valuation: Regeneron Pharmaceuticals, Inc.

Market Cap 66.11B 57.9B 53.33B 49.5B 94B 6,306B 95.27B 638B 248B 3,095B 248B 243B 10,732B P/E 2026 *
16.8x
P/E 2027 * 13.5x
Enterprise Value 58.24B 51.01B 46.98B 43.61B 82.81B 5,556B 83.94B 562B 219B 2,727B 219B 214B 9,455B EV / Sales 2026 *
3.66x
EV / Sales 2027 * 3.16x
Free-Float
72.33%
Yield 2026 *
0.6%
Yield 2027 * 0.68%
1 day+1.93%
1 week+2.85%
Current month+4.21%
1 month+2.26%
3 months-14.84%
6 months-16.32%
Current year-15.81%
1 week 623.89
Extreme 623.89
657.96
1 month 594.9
Extreme 594.9
657.96
Current year 591.52
Extreme 591.52
821.11
1 year 537.45
Extreme 537.45
821.11
3 years 476.49
Extreme 476.4869
1,211.2
5 years 476.49
Extreme 476.4869
1,211.2
10 years 271.37
Extreme 271.37
1,211.2
Manager TitleAgeSince
President 66 31/12/2000
Chief Executive Officer 73 07/01/1988
Director of Finance/CFO 55 04/02/2024
Director TitleAgeSince
Chairman 73 08/06/2023
Director/Board Member 85 31/05/1991
Director/Board Member 85 31/05/1991
Date Insider Type Main position Quantity % Market Cap.
04-30Sell

Director

-100 0.0001%
03-31Sell

Director

100 0.0001%
03-01Sell

Director

100 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
+2.09%+2.85%+18.72%-7.81% 66.11B
+0.35%-2.60%+50.21%+225.76% 55.3B
-1.13%+40.50%+40.50%+40.50% 42.44B
-0.21%+8.04%-50.01%-53.55% 41.28B
+0.95%+17.36%+168.28%-30.85% 32.46B
+1.50%-3.77%+56.89%-26.85% 30.78B
+1.08%+0.84%+68.91%+83.93% 23.1B
-3.65%+9.55%+5.63%+188.26% 20.06B
-0.06%+3.72%+67.55%+135.59% 17.19B
-1.29%+7.97%+76.74%+357.35% 15.23B
Average -0.03%+5.51%+50.34%+91.23% 34.39B
Weighted average by Cap. +0.27%+4.22%+43.37%+67.27%

Financials

2026 *2027 *
Net sales 15.9B 13.92B 12.82B 11.9B 22.6B 1,516B 22.91B 153B 59.74B 744B 59.7B 58.39B 2,581B 17.58B 15.4B 14.18B 13.16B 24.99B 1,677B 25.33B 170B 66.06B 823B 66.01B 64.57B 2,854B
Net income 4.09B 3.58B 3.3B 3.06B 5.81B 390B 5.89B 39.48B 15.36B 191B 15.35B 15.02B 664B 5.13B 4.5B 4.14B 3.84B 7.3B 490B 7.4B 49.57B 19.29B 240B 19.28B 18.85B 833B
Net Debt -7.87B -6.89B -6.35B -5.89B -11.19B -750B -11.34B -75.97B -29.56B -368B -29.54B -28.9B -1,277B -10.52B -9.22B -8.49B -7.88B -14.96B -1,004B -15.16B -102B -39.54B -493B -39.52B -38.65B -1,708B
Logo Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows: - revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%); - revenues from product sales (30%); - revenues from sales of technology licenses and subcontracted research services (4.9%). At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Employees
15,343
Date Price Change Volume
06/07/26 US$649.81 -0.68% 714,338
02/07/26 US$654.27 +4.73% 1,071,604
01/07/26 US$624.72 +0.19% 1,170,657
30/06/26 US$623.54 -1.31% 820,925
Trader
Investor
Global
Quality
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
649.81USD
Average target price
825.27USD
Spread / Average Target
+27.00%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. REGN Stock